ALT Altimmune Inc

Item 5.07 Submission of Matters to a Vote of Security Holders.

The 2017 Annual Meeting was held on October 13, 2017. A total of 13,149,360 shares of common stock were present or represented by proxy at the 2017 Annual Meeting, representing 84.3% of the issued and outstanding shares entitled to vote at the meeting. The proposals voted upon and the final results of the vote were as follows:

Proposal No.  1 : Election of Directors. The results were as follows:

Proposal No.  2 : Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2017. The results were as follows:

Proposal No.  3 : Advisory vote on the Compensation of the Company’s named executive officers as disclosed in the Proxy Statement pursuant to the SEC’s compensation rules (referred to as the “say-on-pay” proposal). The results were as follows:

Proposal No.  4 : Advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers. The results are below. One year received the greatest number of votes. Based on these results, and consistent with the Board’s recommendation, the Board has determined that the Company will hold an advisory vote on executive compensation on an annual basis until the next stockholder advisory vote on the frequency of the advisory vote on executive compensation.

Proposal No.  5 : Vote to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to include a provision pursuant to which the Company will be governed by Section 203 of the DGCL. The results were as follows:

Proposal No.  6 : Vote to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to include a provision to eliminate the ability of stockholders to act by written consent. The results were as follows:

Proposal No.  7 : Vote to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to include a provision to permit the Board to fill vacancies on the Board of Directors. The results were as follows:

Proposal No.  8 : Vote to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to include a provision to give the Board the flexibility to determine on a case-by-case basis as to whether indemnification should be provided by the Company (other than with respect to officers and directors). The results were as follows:

Proposal No.  9 : Vote to approve the amendment and restatement of our Amended and Restated Certificate of Incorporation. The results were as follows:

Proposal No.  10 : Vote, for purposes of complying with Nasdaq Listing Rules 5635(b) and 5635(d), to approve the issuance of shares of the Company’s Common Stock underlying the Company’s Series B Convertible Preferred Stock, par value $0.0001 per share, and related Warrants issued by the Company pursuant to the terms of the Securities Purchase Agreement, dated August 16, 2017, between the Company and the investors named therein. The results were as follows: